# TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian

> **NCT00539669** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 47 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00539669
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2007-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00539669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00539669, "TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00539669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*